Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 21, 2019
Daily News
November 21, 2019
- Evenity Debut, Copycat Entries Set to Jolt Power Map of Japan Osteoporosis Market
November 21, 2019
- A Peek into the Digital Pharmaceutical Industry
November 21, 2019
- Chuikyo Discussing Admission Fee for Schizophrenia Patients on Drug Clozapine, Eyeing Transition to Home
November 21, 2019
- Kyowa Kirin Launches Japan PIII for Acoalan in Preeclampsia
November 21, 2019
- MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…